Dosing Frequency and Receptor Sensitivity in Peptide Research
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
# Dosing Frequency and Receptor Sensitivity in Peptide Research
For Research Purposes Only — Not Intended for Human or Animal Consumption
Receptor desensitization and downregulation are fundamental pharmacological phenomena that affect the sustained efficacy of peptide research compounds.
Receptor Desensitization: The Basics
When a receptor is continuously or repeatedly activated, it undergoes desensitization through several mechanisms:
Phosphorylation (rapid, seconds-minutes): GRK-mediated phosphorylation promotes β-arrestin binding, blocking G protein coupling and terminating signaling.
Receptor internalization (intermediate, minutes-hours): β-arrestin promotes receptor removal from the cell surface. Internalized receptors can be recycled (resensitization) or degraded (downregulation).
Receptor downregulation (chronic, days-weeks): Reduced receptor gene expression and protein levels. Requires new receptor synthesis for recovery.
GHS-R1a Desensitization
- Hexarelin: Significant GHS-R1a desensitization with daily administration; progressive GH response attenuation over 2-4 weeks - Ipamorelin: Less pronounced desensitization — a key advantage for research protocols - MK-677: Despite sustained GHS-R1a activation, clinical studies show sustained GH/IGF-1 elevation over months
Strategies to Minimize Desensitization
- Pulsatile dosing: Once or twice daily injections allow receptor resensitization between doses
- Cycling: Periodic off-periods allow receptor level recovery
- Dose optimization: Minimum effective dose reduces receptor activation rate
- Compound rotation: May reduce desensitization compared to continuous single-compound use
References
- Ionescu, M., & Frohman, L.A. (2006). Pulsatile secretion of GH persists during continuous CJC-1295 stimulation. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797.
- Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.
- Lefkowitz, R.J. (1998). G protein-coupled receptors: new roles for receptor kinases and beta-arrestins. Journal of Biological Chemistry, 273(30), 18677–18680.